Why cervical cancer trial monitoring matters now
Cervical cancer has entered a new era of active clinical development. Pembrolizumab's approval in persistent/recurrent/metastatic disease and tisotumab vedotin's (TV) approval in second-line disease established two distinct treatment mechanisms. The current generation of trials is building on both. The live trial data on this page shows how many are active and recruiting.
Key areas driving new trial registrations:
- Pembrolizumab + TV combinations, testing synergy between checkpoint and TF-targeted ADC
- Next-generation ADCs targeting Tissue Factor (TF) and other cervical cancer antigens
- HPV-specific T cell receptor (TCR) therapies and cancer vaccines
- Neoadjuvant immunotherapy in locally advanced cervical cancer (a rapidly growing segment)
- HER2-targeted agents in HER2-amplified cervical cancer
- Novel VEGF combinations following bevacizumab's established role
Get daily cervical cancer trial digest
free plan, no credit card required. Monitor the cervical cancer trial landscape automatically.
Start Free: No Credit CardA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 | Primary completion moved at least 2 years 3 months later Primary endpoint added | Recruiting |
42 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer… NCT06266338 | Oct 31, 2026 · Estimated | Phase 2 |
37 more on the Completions page. See the calendar →
Active Phase 2/3 cervical cancer trials (2026)
Key Phase 3 and pivotal studies in cervical cancer currently recruiting or in startup:
| NCT ID | Trial / Agent | Sponsor | Status |
|---|---|---|---|
| NCT07216703 | Sacituzumab tirumotecan (MK-2870) + pembrolizumab in 1L/2L cervical cancer | Merck Sharp & Dohme | Recruiting |
| NCT06459180 | Sacituzumab tirumotecan monotherapy vs chemotherapy in recurrent cervical cancer | Merck Sharp & Dohme | Active, Not Recruiting |
| NCT06079671 | Volrustomig (CTLA-4/PD-L1 bispecific) in high-risk locally advanced cervical cancer | AstraZeneca | Recruiting |
| NCT07418749 | SHR-A2102 vs investigator's choice chemotherapy in recurrent/metastatic cervical cancer | Suzhou Suncadia | Recruiting |
| NCT07392060 | WX390 + toripalimab vs investigator's choice in cervical cancer | Shanghai Jiatan Pharmatech | Not Yet Recruiting |
| NCT07061977 | Induction pembrolizumab + chemotherapy followed by pembrolizumab before/after CRT | National Cancer Institute | Recruiting |
| NCT07400536 | Cadonilimab (PD-1+CTLA-4) + chemoradiation in locally advanced cervical cancer | Union Hospital, Tongji Medical College | Recruiting |
| NCT05581121 | Para-aortic lymphadenectomy in locally advanced cervical cancer (PARALA) | Institut Claudius Regaud | Recruiting |
What we monitor for cervical cancer
Configure your cervical cancer profile with the following options:
- Condition keywords: "cervical cancer", "cervical carcinoma", "HPV-positive cancer", "squamous cell carcinoma cervix", "adenocarcinoma cervix"
- Phase filter: Phase 1 for early pipeline, Phase 2/3 for registration-enabling and combination trials
- Sponsor filter: Industry-sponsored only, or all including NCI cooperative group trials
- Status filter: Recruiting only, or all active studies
The cervical cancer treatment landscape in 2026
Tisotumab vedotin follow-on combinations
Tisotumab vedotin's approval validated Tissue Factor as a clinically actionable target in cervical cancer. The innovaTV program is now exploring TV + pembrolizumab, TV + carboplatin, and TV + anti-VEGF combinations in both earlier lines and as maintenance. Competitor TF-targeted programs from other companies are also entering the clinical stage. Tracking these registrations maps the competitive landscape for TF-directed therapy.
HPV-targeted immunotherapy
Cervical cancer's HPV etiology makes it an ideal target for virus-directed immunotherapy. Multiple programs are developing TCR therapies targeting HPV E6 and E7 epitopes, therapeutic vaccines, and engineered T cell products. Several Phase 1/2 trials of HPV-specific cell therapy opened in 2025 and are recruiting at academic centers. This is one of the most distinctive features of cervical cancer clinical development compared to other solid tumors.
Neoadjuvant and organ-preservation approaches
Locally advanced cervical cancer has traditionally been treated with concurrent chemoradiation. A new generation of trials is testing neoadjuvant chemotherapy or immunotherapy before definitive CRT, with the goal of improving response rates and potentially enabling organ-preserving surgery. Phase 3 trial NCT07061977 is testing induction pembrolizumab + chemotherapy in this setting.
Global access and low-resource setting trials
Cervical cancer disproportionately affects women in low- and middle-income countries. Trials examining oral chemotherapy options, single-agent immunotherapy for resource-limited settings, and alternative RT schedules represent a unique component of the cervical cancer trial landscape that is often missed by conventional monitoring approaches.
Who uses cervical cancer trial monitoring
Gynecologic oncology BD teams
Companies developing assets in cervical cancer monitor competitor trial registrations to map the competitive landscape for TF-directed, HER2-directed, and immunotherapy approaches in this indication.
Radiation oncologists and gynecologic surgeons
Specialists treating locally advanced cervical cancer track neoadjuvant and concurrent therapy trial registrations to identify protocols potentially applicable to their patient populations and to understand emerging treatment algorithms.
Global health organizations and patient advocates
Organizations focused on cervical cancer elimination, WHO's 90-70-90 targets, monitor treatment and prevention trial activity to stay current on advances relevant to their advocacy and policy work.
Ready to automate your cervical cancer trial monitoring?
free plan, no credit card required. Setup takes under 2 minutes.
Get the Free DigestFrequently asked questions
Does this cover HPV-positive oropharyngeal cancer as well?
Not by default, but you can add keywords like "HPV-positive head and neck cancer" or "oropharyngeal squamous cell carcinoma" to a separate profile. On Pro ($49/month, or $490/year), you can save up to 10 searches, each feeding the same daily digest.
How current is the cervical cancer trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Cervical Cancer trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
719 active trials, 391 recruiting.
Industry sponsors run 125 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 101.
| Top industry sponsor | Active trials |
|---|---|
| AstraZeneca | 5 |
| Merck (MSD) | 5 |
| Pfizer | 4 |
| Eli Lilly and Company | 3 |
| Akeso | 2 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors… NCT04152499 | Active, Not Recruiting | Completion pushed from Dec 31, 2026 to Nov 30, 2027 | 2026-10-10 |
| Diagnostic Evaluation of Viral Persistence in Cervical Cancer NCT07325682 | Enrolling by Invitation | Primary completion pushed from Jun 30, 2026 to Jun 30, 2030 | 2026-10-09 |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors… NCT05579366 | Recruiting | Interventions modified | 2026-10-08 |
| Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer NCT06977594 | Recruiting | Recruitment opened | 2026-10-08 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With… NCT07216703 | Recruiting | Trial sites expanded: 177 → 180 locations | 2026-10-07 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.